The laboratory assessment of lipid disorders by Vermaak, WJH
All updated lipid guidelines published so
far focus on the concept of ‘ g l o b a l ’ o r
‘ t o t a l ’ risk assessment of coronary heart
disease (CHD) ri s k .1 Tr a d i t i o n a l l y, ri s k -
factor guidelines have been concern e d
with unifa c t o rial assessment — in the
management of hy p e rtension or hy p e r l i p i-
daemia — and this has resulted in undue
emphasis being placed on individual ri s k
fa c t o rs. In practice, p hysicians deal with
the whole patient rather than one aspect of
his or her risk and as clusters of risk fa c-
t o rs may have a multiplicat i ve effect, a n
individual with a number of modest ri s k
fa c t o rs may be at considerably gr e ater ri s k
than a subject with one ve ry high risk fa c-
t o r. Clinical laborat o ries play an indis-
pensable role in this integr ated assessment
and in monitoring the efficacy of any
i n t e rve n t i o n .
Hyperlipidaemia is the most common bio-
chemical abnormality that requires labora-
t o ry inve s t i g ations and monitori n g .2
There are also emerging risk fa c t o rs that
are receiving increasing research at t e n t i o n
such as hy p e r h o m o cy s t e i n a e m i a , c l o t t i n g
factor abnorm a l i t i e s , infectious agents and
i n f l a m m at o ry markers such as C-reactive
protein (CRP) that will impact on labora-
t o ry inve s t i g ations and the role of the labo-
r at o ry in the management of these disor-
d e rs and the complications associated with
t h e m .3 , 4 These emerging risk fa c t o rs fa l l
outside the scope of this review and the
focus and discussion will be on dyslipi-
d a e m i a .
LA BORATORY APPROACH TO
SUSPEC T ED LIPID DISORDERS 
The laborat o ry approach to any pat i e n t
with an abnormality must be conducted in
a logical progr e s s i o n . The following three
c l i n i c o p at h o l o gical questions guide the
diagnostic work-up of the pat i e n t :
• Is there a true hyperlipidaemia? Is the
d e gree of abnormality contri buting sig-
nificantly to the pat i e n t ’s total risk and
will the patient benefit mat e rially by
l owe ring the cholesterol ?
• Is the cause pri m a ry or secondary ?
These secondary causes should be
screened by measuring thy r o i d - s t i m u-
l ating hormone (TSH), g l u c o s e , l i ve r
e n z y m e s , and kidney function.T h e y
should be treated if possible, p rior to
i n i t i ating drug therapy for lipid disor-
d e rs.
• W h at is the nature of this abnorm a l i t y ?
The lipid abnormality may manifest
itself either as a predominantly high
cholesterol abnormality or at the other
end as a predominantly high tri g l y c-
e ride problem.There are also cases
where the patient suffers from a mixe d
or combined dyslipidaemia where both
t ri g l y c e rides (TGs) and total cholesterol
(TC) are elevat e d .
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Lipid guidelines developed by several profession -
al organisations and bodies serve to simplify and
standardise the clinical approach to and manage -
ment of patients at risk for CHD.
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Hyperlipidaemia is the
most common biochemi -
cal abnormality that
requires laboratory
investigations and moni -
t o r i n g .
IS THERE A TRUE 
H Y PERL IPIDA EMI A ?
To answer this question a number
of issues require a closer inspection,
e . g . h ow do we define hy p e r l i p i-
daemia and more specifically the
issues of cut-off points or reference
r a n g e s , intra-individual or biologi-
cal va ri ations as well as analytical
and methodological va ri at i o n s , t h e
s t a n d a r d i s ation of assays and lastly,
which patients should be targeted
for lipid screening.
Hyperlipidaemia and dyslipi-
d a e m i a
Hyperlipidaemia is the term used
to embrace the conditions that
result in raised serum levels of one
or more of  T C , l ow - d e n s i t y
lipoprotein cholesterol (LDLC), o r
T G s , or both TC and TGs. It is,
h owe ve r , not an easy task to define
w h at is meant by ‘ n o rm a l ’ , or low
or high, or what the va rious action
limits should be for a number of
r e a s o n s. The long exposure peri o d
to the lipid abnormality before the
disease becomes clinically manifest
and the high prevalence of lipid dis-
order in the general populat i o n
defy the use of statistical methods
to establish reference ranges.
The altern at i ve approach is to
study the relationship betwe e n
CHD risk and the serum concen-
t r ations of  TC and LDLC in a
p o p u l at i o n . Most of these inve s t i-
g ations produced a curv i l i n e a r
graph and epidemiologists identi-
fied three segments on this gr a p h
based on the steepness of the gr a d i-
e n t , i . e . d e s i r a b l e , b o r d e r l i n e - h i g h
risk and high risk for CHD.5
These curvilinear graphs only apply
to serum TC and LDLC. A seru m
cholesterol of <5.2 mmol/l for T C ,
and 3.4 mmol/l for LDLC we r e
deemed desirable; a value betwe e n
5.2 and 6.2 mmol/l as borderline-
high for TC and >6.2 mmol/l for
TC as high ri s k . The corr e s p o n d-
ing cut-off points for LDLC are 3.4
- 4.1 mmol/l (borderline - high)
and >4.1 mmol/l (high ri s k ) .
These cut-off points became firm l y
entrenched in the minds of the
public and medical frat e rnity dur-
ing the ‘era of unifa c t o rial assess-
m e n t s ’ and even today it is not
unusual to find many patients who
h ave baseline or nat i ve TC levels of
slightly over 6.0 mmol/l and with
no other risk factor for CHD, bu t
who are on statin therapy in an
attempt to dri ve their serum T C
b e l ow 5 mmol/l!  This approach is
inherently flawed or even danger-
ous since it can lead to ove r - t r e at-
ment or inappropri ate treatment of
individuals who are not at ri s k , o r
otherwise under-treatment of
p atients who are truly at high ri s k
and who may require a far more
a g gr e s s i ve approach to bring their
TC concentration to levels we l l
b e l ow 5 mmol/l. The fa l l a cy of
t r e ating the TC cut-off points of
5.2 and 6.2 mmol/l as absolute ri s k
cut points regardless of the clinical
risk profile is further illustrated by
s e veral studies which found that as
m a ny as 20% of men with con-
f i rmed CHD have serum TC <5.2
m m o l / l .6 Most of these subjects
with almost desirable TC leve l s ,
h owe ve r , had low HDLC leve l s
(<0.9 mmol/l). It is for this reason
t h at the term ‘ d y s l i p i d a e m i a ’ i s
regarded as more appropri ate than
‘ hy p e r l i p i d a e m i a ’ , although many
use it interchangeably. The afore-
mentioned realisation of the limita-
tions and inappropri ate use of the
proposed cholesterol cut points
prompted researchers to redefine
the concept of hyperlipidaemia or
d y s l i p i d a e m i a .
A ‘contextualised’ definition of
abnormal serum cholesterol or
hyperlipidaemia 
The integr ated risk approach which
is currently emphasised by all
g u i d e l i n e s1 has provided the back-
ground and plat f o rm to define
a b n o rmal or undesirable choles-
terol leve l s. This operational defini-
tion is required when assessing the
need for lipid lowe ring therapy and
s t ates that dyslipidaemia is present
when serum TC is at least 5
m m o l / l , or LDLC at least 3 mmol/l
or HDLC <0.9 mmol/l a n d the 10-
year risk of developing CHD is
> 3 0 % .7 The essence of this defini-
tion is that the lipid values should
be judged and acted upon against
the clinical background and the
total risk estimate for CHD.
Global risk assessment tools
The assessment of the 10-ye a r
CHD risk is done by using one of
s e veral risk assessment tools 
(See Website addresses,Table I).
The different risk assessment tools
require slightly different sets of
d at a , but most include the follow-
i n g : g e n d e r , age (ye a rs ) , s m o k i n g
s t at u s , presence or absence of dia-
b e t e s , blood pressure (mmHg),T C
( m m o l / l ) , HDLC (mmol/l), p r e s-
ence or absence of ECG evidence
of left ve n t ricular hy p e rt r o p hy.
The role of other lipid and
lipoprotein fractions in the inte-
grated assessment of the bio-
chemical risk profile 
S e rum HDLC
The risk associated with high TC is
p ri m a rily due to high levels of
LDLC but there is a strong, i n d e-
pendent and inve rse associat i o n
b e t ween HDLC and CHD ri s k .8
L ow HDLC levels increase the ri s k
for CHD, e ven when TC is below
5.2 mmol/l, a pat t e rn present in up
to 20% of men with confirm e d
C H D.6 In many studies, m e a s u r e s
of HDLC or the ratio of
TC/HDLC are better predictors of
CHD risk than serum TC alone.9
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S e rum tri g l y c e ri d e s
The importance of TGs has
remained uncertain for a long time.
In a meta-analysis, but not alway s
in individual studies, increased TG
values have been shown to be an
independent CHD risk fa c t o r ,
especially in wo m e n .1 0 I n c r e a s e d
TG values are corr e l ated with
decreased HDLC va l u e s. T h e
c o m b i n ation of high TG values and
l ow HDLC values often occurs in
a s s o c i ation with other CHD ri s k
fa c t o rs such as hy p e rt e n s i o n , d i a-
betes mellitus or milder forms of
insulin resistance.1 1 This form s
p a rt of what has become known as
syndrome X or plurimetabolic syn-
d r o m e . The National Cholesterol
E d u c ation Program (NCEP) A d u l t
Tr e atment Panel II suggests that a
s e rum TG level of between 2.3 -
4.5 mmol/l is compatible with a
borderline to high risk for CHD.1 2
More recent epidemiological dat a
suggest that a fasting TG level >1.7
mmol/l already denotes a border-
line to high-risk va l u e .1 3
S e rum Lp(a)
An increased Lp(a) value is likely
to be a significant independent
CHD risk fa c t o r.1 4 This concept is
s u p p o rted by many case control
studies and  9 of 13 prospective
s t u d i e s.1 5 Problems associated with
Lp(a) measurement include lack of
a s s ay standardisation and consider-
able heterogeneity within the pro-
t e i n .1 6 When calibrated to total
mass of the part i c l e , an Lp(a) va l u e
of >40 mg/dl is clearly above the
90th percentile, but many authori-
ties feel that a value >30 mg/dl is
already a high-risk va l u e .1 7 Fa m i l i a l
Lp(a) excess (>90th percentile) is a
highly heritable disorder found in
15 - 20% of kindreds with prema-
ture CHD. Niacin administrat i o n
has been shown to lower Lp(a) lev-
els as well as to reduce CHD mor-
bidity and mort a l i t y. For this rea-
son certain authors recommend
t h at Lp(a) levels be measured in
p atients who are candidates for
d rug therapy, especially those with
CHD and a strong family history of
C H D.1 8
S e rum apolipoproteins
In some studies low Apo A1 va l u e s
and increased ApoB concentrat i o n s
as well as smaller LDL part i c l e s
h ave been reported to be superi o r
to HDLC and LDLC as markers
for CHD.19 O t h e rs , a g a i n , h ave
found that particle size is not an
independent risk factor after con-
trolling for the effect of β- b l o c k e rs
and LDLC and HDLC concentra-
t i o n s.2 0 Because of cost considera-
tions these determ i n ations cannot
be recommended for CHD ri s k
assessment at this stage. More dat a
from large-scale prospective studies
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CHD risk assessment tool                                       Source
Joint British recommendations View  





Joint British recommendations http://www.bnf.org/CalculatorHome,htm




Sheffield table for primary http://bmj.com/content/vol320/issue
prevention of CHD (3rd edition, 7236/images/large/wale.3599.fl.jpeg
corrected)
Online calculator
Framingham function for risk http://www.cardiocrisk,org.uk/
estimation (hint, look at the bottom of the screen and click
on the numbers 1,2,3,4,5)
View
New Zealand tables for absolute 5- http://cebm.jr2.ox.ac.uk/docs/prognosis,html
year risk of a cardiovascular event
Download
A suite of algorithms and risk http://www.medal.org
prediction tools
Download
UKPDS risk engine: http://www.dtu.ox.ac.uk/
risk in people with type 2 diabetes
Download
Indana risk calculator: http://www.riskscore.org.uk
risk in people with hypertension
Table I. Website addresses
are required before this parameter
can be included in the biochemical
risk profile assessment.
Who should be investigated for
h y p e r l i p i d a e m i a ?
It is not wo rth while to measure
cholesterol concentrations in peo-
ple whose risk is less than 15% ove r
10 ye a rs.This statement is based
on the assumption that these indi-
viduals have average cholesterol va l-
u e s. Testing for dyslipidaemia
should be targeted at those gr o u p s
at the gr e atest risk so that candi-
d ates for treatment can be efficient-
ly identified.
What variables can influence the
validity of the results?
A c c u r ate determ i n ation of seru m
lipids and lipoproteins is dependent
on control of both analytical and
pre-analytical fa c t o rs. P r e - a n a l y t i-
cal va ri ation in subjects results
from differences in lifestyle, a l t e r e d
metabolism due to disease, t h e
source of the specimen and the
conditions of sample collection.
Va ri ation can arise from biologi c a l ,
b e h avioural and clinical fa c t o rs as
well as va riability in specimen col-
lection and handling. (See Table II
for recommendations for minimis-
ing pre-analytical va ri at i o n ) .
S e rum TC is the most stable lipid
a n a l y t e . B e t ween days biologi c a l
va ri ation averages 6.1%, a l t h o u g h
some individuals may va ry up to
1 1 % . There is no diurnal va ri at i o n
and the seasonal va ri ation is no
more than 2.5%.2 1 In women T C
m ay fluctuate during the menstru a l
cy c l e , ave r a ging 10 - 20% lower in
the luteal and menstrual phases.
For the average wo m a n , TC leve l s
increase by about 0.31 mmol/l
around ov u l ation and fall to a nadir
d u ring menstru at i o n .2 1
TG l e vels show marked intra-indi-
vidual va ri at i o n . E ven excluding
the marked postprandial fluctua-
t i o n , fasting TGs differ by an ave r-
age of 23% over one or more
m o n t h s , and in some persons may
f l u c t u ate as much as 40% around
the mean va l u e .2 2 The ave r a g e
d i u rnal va ri ation is ± 30% with the
nadir at approx i m ately 03:00 and
the peak values in mid-aftern o o n .
Because of this marked random
va ri at i o n , it is difficult to assess sea-
s o n a l , m e n s t rual and other fluctua-
tions of  T G s.2 3
HDLC levels show an ave r a g e
intra-individual va ri ation of 7%
over one month to a ye a r , but sel-
dom differ by more than 12%.
Seasonal va ri ation in HDLC is
comparable with that of  T C .2 4
Whether LDLC is measured direct-
ly or deri ved from measurements of
T C , HDLC and TG, b i o l o gi c a l
va riability is similar at an average of
9 . 5 % .
Lp(a) shows an average biologi c a l
va ri ation of 8.6%.1 8
The impact of lifestyle elements
on lipid, lipoprotein and
apolipoprotein levels   
The major behavioural fa c t o rs that
e xe rt an effect on these parameters
a r e : d i e t , o b e s i t y, cigarette smok-
i n g, alcohol and caffeine intake,
e xercise and stress. Since these
lifestyle elements are controllable, i t
is imperat i ve that subjects maintain
their behaviour for several day s
before blood specimens for lipid
testing are obtained. The effect of
food ingestion on lipid measure-
ments has long been established. A
controlled dietary study showe d
t h at ingestion of a typical fat - c o n-
taining meal caused a significant
increase in TGs that persisted for at
least 9 hours.2 5 VLDLC also
increases while LDLC falls signifi-
c a n t l y. Both changes persist for at
least 9 hours.
The duration of fasting has pro-
found effects on TC and TG l e ve l s.
TC and TGs increase an average of
25% after 1 week of fa s t i n g, fa l l i n g
to baseline after 3 we e k s.
Refeeding causes a 13% fall in T C
but an 86% increase in TGs.2 6
Anticoagulants and preservatives  
C u rrent recommendations for cut-
off points are based on ordinary
s e rum samples (red top va c u u m
t u b e s ) . Because of its osmotic
e f f e c t , E D TA causes a method-
dependent art e factual fall in most
lipid and lipoprotein concentra-
t i o n s , but a paradoxical rise in
H D L C .2 7 The average difference
b e t ween serum and plasma using
tubes with EDTA is now close to
5% because of increases in the con-
tent of EDTA in the blood collec-
tion tubes by the manufa c t u r e rs.2 8
Use of other anticoagulants such as
ox a l ate and citrate is associat e d
with even gr e ater osmotic fluid
s h i f t s. H e p a rin does not produce
fluid shifts and appears to be an
acceptable altern at i ve for TC mea-
s u r e m e n t .2 9 Howe ve r , it activat e s
lipoprotein lipase both in vitro a n d
in vivo. Most serum separat o r
tubes do not appear to affect the
results of lipid measurement and
are gaining favour as they are more
c o nvenient for routine chemistry
l a b o r at o ri e s.
C a p i l l a ry versus venous blood 
Conflicting results have been
obtained from lower TC levels in
c a p i l l a ry blood, to similar results to
higher va l u e s.3 0 The use of a stan-
dardised protocol for collecting
c a p i l l a ry samples can produce
results that agree closely with
venous plasma.
Haemoconcentration   
A patient who stands for 5 minutes
will experience an apparent
increase in lipid concentration of
9% and a further increase to 16%
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It is not worth while
to measure choles -
terol concentrations
in people whose risk
is less than 15%
over 10 years
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after 15 minutes.3 1 This can be
minimised by seating a patient for
at least 15 minutes before
ve n i p u n c t u r e . A tourniquet can also
cause significant haemoconcentra-
t i o n . After 1 minute there is no
significant change in TC or protein
c o n c e n t r at i o n s. Howe ver after 2
minutes the apparent TC concen-
t r ation increases up to 5% and after
5 minutes apparent increases of
1 0 - 15% can occur. If a tourn i-
quet remains for 15 minutes duri n g
p h l e b o t o my, lipid measurements
increase by 20 - 40%.3 2
Specimen storage  
Specimens for most lipid testing are
stable at 0 - 4 ° C . S e rum does not
fully freeze until about -40°C.3 3
ApoB can decrease slightly when
f r o z e n , but other lipid components
appear stable when frozen for up to
6 months.
A n a l ytical considerations  
TC measurements
In 1988 the laborat o ry standardisa-
tion panel of the NCEP released its
r e p o rt on the status of the measure-
ment of serum TC in the USA.3 4
For the first time guidelines we r e
established for the accuracy and
precision of serum TC determ i n a-
t i o n s. As of 1992 laborat o ries we r e
expected to be able to attain T C
values that are within 3% of the
‘ t rue va l u e ’ as defined by a defini-
t i ve method, and to have a total
imprecision (CV) of  < 3%.3 3
These comparat i vely tight stan-
dards were established in order to
minimise the possibility of inappro-
p ri ately reporting a TC va l u e . Fo r
e x a m p l e , if the total imprecision
were 10% a specimen in the range
of 5.2 could be reported as 6.2
a n d , c o nve rs e l y, a high TC leve l
could be reported as acceptable.
Both possibilities have their own set
of undesirable consequences.
Measurements of TGs
At this stage, no true definitive or
reference method has been estab-
lished for the measurement of
TGs.3 4 Due to the broad biologi c a l
va riability of TGs , the accuracy of
measurement has not been of ove r-
whelming importance in the clini-
cal laborat o ry, except for the calcu-
l ation of the LDLC by the use of
the Fri e d e wald equat i o n . With the
emergence of direct measurements
of LDLC the value of the measure-
ment of TGs may be lessened fur-
t h e r. It should be borne in mind
t h at the Fri e d e wald formula cannot
be used for values obtained on
s e rum from non-fasting individuals
or those whose TGs values exceed
4.5 mmol/l. M o r e ove r , there is
considerable va riability in calculat-
ed LDLC concentrations when
TGs concentrations are 2.3 - 4.5
mmol/l as compared with va l u e s
obtained by ultracentri f u g at i o n .3 5
HDLC measurements
The importance of accurate HDLC
measurements was emphasised by
the following stat e m e n t : ‘One has
to be able to measure accurately in
the range below 1.30 mmol/l as a
difference of less than 0.13 mmol/l
is used to define an individual’s
ri s k .’3 6 The NCEP has set the fol-
l owing analytical goals for HDLC
m e a s u r e m e n t s : precision <4%;
a c c u r a cy <5% and total allowa b l e
e rror <13%.
Because such important treat m e n t
decisions are made on individual
• Lipid and lipoprotein profile should only be measured when the individual is in a steady metabolic state.
• Subjects should maintain their usual diet and weight for at least 2 weeks prior to the determination of
their lipids or lipoproteins.
• Multiple measurements should be performed within 2 months, at least 1 week apart, before making a
medical decision about further action.
• Subjects should not perform vigorous physical activity during the 24 h prior to testing.
• Fasting or non-fasting specimens can be used for TC testing. However, a 12-h fasting specimen is required
for TG and recommended for lipoproteins.
• The subject should be seated for at least 5 min before specimen collection.
• The tourniquet should not be kept on more than 1 min during venepuncture.
• TC, TG, and HDL-C concentrations can be determined in either serum or plasma. When EDTA is used as
the anticoagulant, plasma should be immediately cooled to 2 - 4°C to prevent changes in composition and
values should be multiplied by 1.03.
• For TC testing, serum can be transported either at 4°C or frozen. Storage of specimens at –20°C is ade-
quate for TC measurement. However, specimens must be stored frozen at –70°C or lower for TG and
lipoprotein/apolipoprotein testing.
• All blood specimens should be considered potentially infectious and handled accordingly.
Table II. Recommendations for minimising pre-analytical variation
A patient who
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lipid levels it becomes extremely
i m p o rtant to have rigorous control
over as many of the aforementioned
va riables as possible. All laborat o-
ries or phlebotomy points should
h ave standard operating procedures
in place to minimise the va ri a b i l i t y.
A c c u r a cy and repeatability of mea-
surements are equally import a n t .
Clinical laborat o ries should ideally
s t ate their accuracy and precision
with each lipid report produced on
such patients so that dose response
o b s e rvations and adjustments can
be made on credible and reliable
l a b o r at o ry dat a .
What laboratory tests should be
p e rformed on patients suspect-
ed of having hyperlipidaemia?
Initial tests. N o n - fasting seru m
total cholesterol and HDL choles-
terol (which are practically unaf-
fected by meals).
Tests prior to trea t m e n t . Fa s t i n g
lipid profile, including TG leve l .
S e rum lipid measurements are sub-
ject to biological va ri ation and ide-
ally require at least 3 measurements
to assess their true mean leve l s.
L e vels of  TG are raised by fat in
recent meals and this inva l i d at e s
the calculation of LDL leve l s.
• Baseline tests. C r e atine kinase
(CK) and aspart ate aminotrans-
ferase (AST) or alanine amino-
transferase (ALT) tests should
be done before starting treat-
ment with a statin or a fibrat e .
• E ve r y 8 - 12 weeks w h i l e
t i t r a ting therapy (statin or
f i b r at e ) . Fasting lipid profile,
AST or A LT, C K .
• E ve r y year while on stab l e
therapy (statin or fibra t e ) .
Fasting lipid profile, AST or
A LT, C K .
The frequency of metabolic moni-
t o ring should be increased in renal
i m p a i rment and when a statin and
a fibrate are co-prescri b e d .
IS THE DISORDER PRIM A-
RY OR SECONDA RY ?
Once a patient has been confirm e d
as having an abnormal lipid profile,
s e c o n d a ry underlying causes of
dyslipidaemia need to be excluded.
The confirm ation of hy p e r l i p i-
daemia requires at least 3 measure-
ments to assess their true mean va l-
u e s.
The following routine laborat o ry
tests are indicat e d :
• fasting plasma glucose
• l i ver function tests
• renal function tests
• t hyroid stimulating horm o n e
• muscle enzyme: c r e at i n i n e
k i n a s e .
See also the article on secondary
d y s l i p i d a e m i a s , p. 365 of this issue.
A ET IOLOGICAL DI AGNO-
SIS OF DYSL IPIDA EMI A
The classification most suited to
clinical practice is discussed in the
a rticle on the clinical approach to
dyslipidaemia (p. 370 of this issue).
It is based on the measurement of
the 2 common lipids, defining the
derangements as hy p e r c h o l e s t e r o l-
a e m i a , hy p e rt ri g l i c e ridaemia or
m i xed hy p e rt ri g l i c e ri d a e m i a .T h e
measurement of HDLC and
LDLC further defines the at h e r o-
genic ri s k . An exact aetiologi c a l
diagnosis is not possible for the
bulk of moderate hy p e r l i p i d a e m i a s
but specific diagnoses are of gr e at
i m p o rtance in the presence of
extremes of dyslipidaemia, ve ry
p r e m ature cardiovascular disease or
tendinomas or cutaneous xan-
t h o m at a . In many of these settings
genetic counselling is required and
special inve s t i g ations may be per-
f o rmed at tert i a ry clinics.
Re f e rences available on re q u e st .
IN A NUTSHELL
The older ‘traditional’ lipid guidelines
have placed undue emphasis on individ-
ually high-risk factors such as cholest e ro l .
The aim of the TC cut-off points of 5.2
mmol/l and 6.2 mmol/l was to identify as
many subjects as possible who have bor-
derline to high risk and high risk for CHD
re s p e c t i v e l y. This approach created the
i m p ression that all subjects with serum
c h o l e st e rol greater than 5.2 or 6.2
mmol/l are at a higher or high risk for
CHD and it ignored the fact that a clust e r
of coexisting, mildly abnormal risk factors
may confer a much higher risk on an
individual than only one very high risk
f a c t o r.
The latest guidelines suggest that these
cut-off points should no longer be inter-
p reted in isolation but rather against the
b a c k g round of the global CHD risk of a
patient. This will avoid unnecessa ry tre a t-
ment of patients who are not really at risk
or alternatively identify patients who
re q u i re aggressive lipid-lowering therapy
even though their serum TC or LDLC
may be only moderately elevated or may
indeed be within the so-called desirable
r a n g e .
The re p e rt o i re of laboratory invest i g a-
tions to fully assess the patient’s total risk
for CHD needs to be done in a logica l
p ro g ression in order to answer the fol-
lowing 5 crucial clinical quest i o n s :
• Which patients should be ta rgeted for
lipid scre e n i n g ?
• What variables can influence the
validity of the results that need to be
c o n t ro l l e d ?
• What laboratory tests should be done
on them?
• What further laboratory tests are
re q u i red in patients whose scre e n i n g
results just i fy possible interv e n t i o n ?
• What laboratory tests are indicated in
monitoring patients who receive lipid-
lowering drugs?
The subsequent management of the dys-
lipidaemic patient will depend on the
n a t u re and severity of the disord e r, i.e.
p redominant hyperc h o l e st e rolaemia, pre-
dominant hypertriglyceridaemia or a
combined disord e r.
M o re complex disorders such as type III
( b road B band disease) and atypical pre-
s e n tations or clinical syndromes should
be re f e r red to specialist lipid clinics for
f u rther invest i g a t i o n s .
Lipid guidelines and risk assessment
algorithms should be used to supple-
ment, not replace clinical judgement.
